Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study
Published May 30, 2008 · T. Baptista, E. Uzcátegui, Nairy Rangel
Psychiatry Research
70
Citations
4
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeawayMetformin and sibutramine combined showed similar weight loss in olanzapine-treated chronic schizophrenia patients, but lacked efficacy for metabolic control except for preventing triglyceride increase.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.